Suggestions
Andrei Afanasiev
VC | R&D in Pharma & Biotech | Startup Advisor
Andrei Afanasiev is a distinguished CEO and Head of Research and Development, leveraging over 15 years of experience in the pharma and biotech industry. With a solid background in R&D, business development, and venture capital projects, Andrei's expertise spans from the preclinical stage to stage III clinical trials in drug development.
Having founded and led 3 successful startups in bioinformatics SaaS, genetic testing, and cancer treatment, one of which achieved a lucrative exit through M&A with a strategic investor, Andrei has a proven track record of entrepreneurial success.
As a former R&D Director at a pharmaceutical company overseeing a substantial annual budget of $15M, Andrei is skilled in research strategy development, preclinical study management, and project oversight within the pharmaceutical sector. He excels in fostering collaboration across cross-functional teams and stakeholders, including production, medical, marketing, and regulatory departments.
Andrei's scientific proficiency extends to machine learning and genetics, evidenced by over 100 public talks, 7 authored papers, and 2 secured patents. Beyond his professional endeavors, Andrei is passionate about science popularization, community building, and actively mentors startups and students.
Andrei Afanasiev pursued his education in Specialist Nuclear Physics at Lomonosov Moscow State University (MSU) and has extensive experience with prominent organizations in various roles, including Venture Partner at Sky High VC, Advisor at Focal Reasonance, and Scientific Consultant at Unison, among others.
Highlights
As part of the Innovation Week in Buenos Aires, I attended a fantastic event, Network to the Top: Jazz Night, organized by Qroom 360.
A big thank you to Ale Bustos -JMT-Speaker🔷 for inviting me!
It was an unforgettable evening of immersing myself in Argentine culture and networking at the highest level – especially since we were graced by a performance from the legendary Argentine rock musician, Charly García!
The venue also deserves special mention – the iconic Faena Buenos Aires
I look forward to continuing to work with QRoom LLC and participating in their events.
#CharlyGarcía #LeyendaDelRock #NocheDeVinoYJazz #HotelFaena #InnovationTechWeek
Como parte de la Semana de la Innovación en Buenos Aires, asistí a un evento fantástico, Network to the Top: Jazz Night, organizado por Qroom 360. Muchas gracias a Ale Bustos -JMT-Speaker🔷 por invitarme! Fue una noche inolvidable de inmersión en la cultura argentina y de networking al más alto nivel, sobre todo porque nos deleitó con su música el legendario rockero argentino, Charly García! El lugar también merece una mención especial: el icónico hotel Faena, una joya de Buenos Aires. Espero seguir trabajando con Qroom 360 y participar en sus eventos.
(Castellano a continuación)
It seems like no one talks about the pandemic anymore, but I'm excited to share that our article on Cansino's Phase 3 clinical trial of the Convidecia vaccine has been published in PLOS One magazine. It's been three years since I organized these studies at Petrovax, and I'm proud of the truly international cooperation that made it possible. Scientists from Canada, China, and Russia worked together to tackle a common problem, and although the Convidecia vaccine didn't reach the same scale as Pfizer, Moderna, AZ, or Sputnik V, it still protected millions of people and saved thousands of lives.
Looking back on those challenging pandemic days, I feel grateful for everyone who was involved. Mikhail Tsyferov Vitalina Dzutseva, MD Anton Tikhonov Grigory Efimov
https://lnkd.in/dNeBeMUe
Nadie habla ya de la pandemia, y la revista PLOS One finalmente ha publicado nuestro artículo sobre el ensayo clínico de fase 3 de la vacuna Convidecia de Cansino. Organicé estos estudios hace 3 años cuando trabajaba en Petrovax, ¡y fue un gran ejemplo de cooperación verdaderamente internacional! Personas de Canadá, China y Rusia trabajaron juntas en un problema común. Y aunque esta vacuna no se convirtió en tan masiva como las vacunas de Pfizer, Moderna, AZ y Sputnik V, aún protegió a millones de personas y evitó miles de muertes, lo que significa que no trabajamos en vano.
Gracias a todos los involucrados, recuerdo estos difíciles días de pandemia con calidez.
#covid19research #vaccines #cansino #petrovax
